May 23 (Reuters) - Biotech company Caris Life Sciences

filed its paperwork to go public in the U.S. on Friday as the

stock market shows signs of recovery after tariff shocks.

Irving, Texas-based firm reported a revenue rise to $412.3

million in 2024 compared with $306.1 million in 2023, according

to the regulatory filing.

Activity in the U.S. IPO market had declined after a strong

start in 2025 due to an ever-evolving tariff environment,

geopolitical uncertainty and inflationary pressures.

However, companies in sectors perceived as less sensitive to

economic headwinds are pushing ahead with their initial public

offerings.

The company's stock will trade on Nasdaq Global Select

Market under the symbol "CAI."

BofA Securities, J.P.Morgan, Goldman Sachs ( GS ) and Citigroup ( C/PN ) are

the lead underwriters for the offering.

Founded in 2008, Caris is a precision medicine company that

provides uses molecular profiling, AI and data analysis to

analyze and guide treatments, therapy and drug development for a

disease.

Healthcare IPOs on U.S. exchanges have fetched $7.1 billion

in 2024, compared with $2.8 billion a year ago, according to the

data compiled by LSEG.